Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Free Cash Flow (2016 - 2025)

Immucell's Free Cash Flow history spans 16 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 493.81% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $2.5 million, up 598.93%, while the annual FY2025 figure was $2.5 million, 598.93% up from the prior year.
  • Free Cash Flow reached $1.6 million in Q4 2025 per ICCC's latest filing, up from -$1.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $1.6 million in Q4 2025 to a low of -$3.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$545814.2, with a median of -$292685.0 recorded in 2021.
  • Peak YoY movement for Free Cash Flow: plummeted 2289.01% in 2022, then skyrocketed 493.81% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$116701.0 in 2021, then tumbled by 2289.01% to -$2.8 million in 2022, then grew by 10.31% to -$2.5 million in 2023, then soared by 110.48% to $262037.0 in 2024, then surged by 493.81% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Free Cash Flow are $1.6 million (Q4 2025), -$1.8 million (Q3 2025), and $1.4 million (Q2 2025).